MAIA Biotechnology(MAIA)
CHICAGO, IL
Biotechnology1 H-1B visas (FY2023)Focus: Peptide Cancer Therapies
MAIA Biotechnology is a life sciences company focused on Peptide Cancer Therapies.
Oncology
Funding Stage
PUBLIC
Open Jobs
0
Products & Portfolio (8)
2 discontinued products not shown
ANGIOMAX RTU
bivalirudin
Peak
INTRAVENOUS · SOLUTION
Thrombin Inhibitors
2019
0
BACLOFEN
baclofen
Post-LOE
INTRATHECAL · INJECTABLE
GABA A Agonists
2019
30
BACLOFEN
baclofen
Post-LOE
INTRATHECAL · INJECTABLE
GABA A Agonists
multiple sclerosis
2019
30
BACLOFEN
baclofen
Post-LOE
INTRATHECAL · INJECTABLE
GABA A Agonists
multiple sclerosis
2021
30
LEVOTHYROXINE SODIUM
levothyroxine sodium anhydrous
Post-LOE
INTRAVENOUS · POWDER
synthesis. Triiodothyronine (T 3 ) and levothyroxine (T 4 ) diffuse into the cell nucleus and bind to thyroid receptor proteins attached to DNA. This hormone nuclear receptor complex activates gene transcription and synthesis of messenger RNA and cytoplasmic proteins. The physiological actions of thyroid hormones are produced predominantly by T 3 , the majority of which (approximately 80%) is derived from T 4 by deiodination in peripheral tissues.
myxedema coma
2018
30
SINCALIDE
sincalide
Peak
INTRAVENOUS · POWDER
2022
0
SODIUM PHENYLACETATE AND SODIUM BENZOATE
sodium phenylacetate and sodium benzoate
Post-LOE
INTRAVENOUS · SOLUTION
2017
30
SODIUM PHENYLACETATE AND SODIUM BENZOATE
sodium phenylacetate and sodium benzoate
Peak
INTRAVENOUS · SOLUTION
2021
30
Pipeline & Clinical Trials
ateganosine
Resectable Hepatocellular CarcinomaClinical Trials (1)
NCT07446257THIO and Cadonilimab in Resectable Hepatocellular Carcinoma
Phase 16-Thio-2'-Deoxyguanosine
Carcinoma, Non-Small-Cell LungClinical Trials (1)
NCT05208944THIO Sequenced With Cemiplimab in Advanced NSCLC
Phase 26-Thio-2'-Deoxyguanosine
Carcinoma, Non-Small -Cell LungClinical Trials (1)
NCT06908304A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 10 approved products, 3 clinical trials
Top TAs: Neurology, Cardiovascular, Gastroenterology
H-1B (2023): 1 approval
SEC Filings: 2 available
Portfolio Health
Growth1 (10%)
Peak4 (40%)
Post-LOE5 (50%)
10 total products
Therapeutic Area Focus
Neurology
3 marketed
Cardiovascular
1 marketed
Gastroenterology
1 marketed
Infectious Diseases
1 marketed
Oncology
1 marketed
Marketed
Pipeline
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub